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Abstract
Celiac Disease (CD) occurs in patients with Type 1 Diabetes (T1D) ranging the prevalence of 4.4-11.1% versus 0.5%
of the general population. The mechanism of association of these two diseases involves a shared genetic
background: HLA genotype DR3-DQ2 and DR4-DQ8 are strongly associated with T1D, DR3-DQ2 with CD. The
classical severe presentation of CD rarely occurs in T1D patients, but more often patients have few/mild symptoms
of CD or are completely asymptomatic (silent CD). In fact diagnosis of CD is regularly performed by means of the
screening in T1D patients. The effects of gluten-free diet (GFD) on the growth and T1D metabolic control in CD/
T1D patient are controversial. Regarding of the GFD composition, there is a debate on the higher glycaemic index
of gluten-free foods respect to gluten-containing foods; furthermore GFD could be poorer of fibers and richer of
fat. The adherence to GFD by children with CD-T1D has been reported generally below 50%, lower respect to the
73% of CD patients, a lower compliance being more frequent among asymptomatic patients. The more severe
problems of GFD adherence usually occur during adolescence when in GFD non compliant subjects the lowest
quality of life is reported. A psychological and educational support should be provided for these patients.
Keywords: Diabetes, Celiac disease, Genetic background, HLA, Dietetic compliance, Glycaemic index, Gluten free
diet, Quality of life
Introduction
Type 1 Diabetes Mellitus (T1D) is frequently associated
to other autoimmune conditions. These conditions can
severely affect clinical management of the disease, espe-
cially in paediatric age.
T h em o s tf r e q u e n ta r ea u t o immune thyroid disease
(AIT), celiac disease (CD), Addison’s disease (AD) and
vitiligo. These diseases are associated with organ-specific
autoantibodies: AIT with thyroid peroxidase (TPO) and
thyroglobulin autoantibodies (TG), CD with endomysial
(EMA) and transglutaminase (TTG) autoantibodies, and
AD with adrenal autoantibodies. Using these autoantibo-
dies, organ-specific autoimmunity may be often detected
before the development of clinical disease, in order to
prevent significant morbidity related to unrecognized
disease [1]. These diseases are very often clustered in
t h es a m ei n d i v i d u a la n das h a r e dg e n e t i cb a c k g r o u n d
probably explains this association [2].
Genetics
The majority of autoimmune endocrine diseases, includ-
ing T1D, are inherited as complex genetic traits. Multi-
ple genetic and environmental factors interact with each
other to confer susceptibility to these disorders. Genetic
risk factors associated with T1D, ATD, CD and AD
include HLA genes and non-HLA genes.
HLA DR4 and DR3 are strongly associated with T1D
and approximately 30-50% of patients are DR3/DR4 het-
erozygotes. The DR3/DR4 genotype confers the highest
diabetes risk with a synergic mode of action, followed by
DR4 and DR3 homozygosity, respectively. The HLA-DQ
(particularly DQ 2 and DQ8) locus has been found to be
the most important determinant of diabetes susceptibility.
Approximately 90% of individuals with T1D have either
DQ2 or DQ8, compared to 40% of the general population
[3]. So, the highest-risk human leukocyte antigen (HLA)
genotype for T1D is DR3-DQ2, DR4-DQ8.
DR3-DQ2 shows a strong association with CD; homo-
zygosity for DR3-DQ2 in a population with T1D carries a
33% risk for the presence of TTG autoantibodies [4].
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tion to T1D and other autoimmune diseases, such as
MIC-A, PTPN22, CTLA-4 [1].
Epidemiology
Traditional studies, both in children and adults, have
shown that CD occurs in patients with T1D with a preva-
lence that varies from 4.4 to 11.1% compared with 0.5%
of the general population (Table 1 for references from)
[5-14]. The mean age at diagnosis of classical CD is com-
monly around 2-3 years, while the mean age at diagnosis
of T1D is 7-8 years. The age at onset of T1D is younger
in patients with the double disease than in those with
only T1D [15]. The risk of CD is negatively and indepen-
dently associated with age at onset of diabetes, with an
higher risk being seen in children age < 4 years than in
those age > 9 years [16]. In patients with T1D, diabetes is
usually diagnosed first, CD precedes diabetes onset only
in 10-25% [16,17], while generally CD diagnosis in T1D
patients occurs, trough the screening performed at dia-
betes onset, in 70-80% of patients with a median age > 8
years. Some authors hypothized that in genetically sus-
ceptible patients one disease could predispose to another.
Particularly, it has been suggested that untreated (latent
or silent) CD could be an immunological trigger and
induce diabetes and/or thyroid disorders due to gluten as
a driving antigen [18]. In accordance with this, the preva-
lence of autoimmune disorders in CD is closely related to
age at diagnosis or, in other words, to the duration of
exposure to gluten [19] and thyroid-related antibodies
tend to disappear during twelve months of gluten-free
diet, like CD-related antibodies [20]. However, at present,
it is unknown whether treatment of CD reduces the like-
lihood of developing autoimmune disorders, or changes
their natural history and actually others found no corre-
lation between duration of gluten exposure in adult CD
and risk of autoimmune disorders [21].
CD clinical symptoms
The most severe CD-related symptoms are generally
related to gastrointestinal malabsorption and include mal-
nutrition, failure to thrive, diarrhea, anorexia, constipation,
vomiting, abdominal distension, and pain. These features
are more common in children younger than three years of
age. Non-gastrointestinal symptoms of CD include short
stature, pubertal delay, fatigue, vitamin deficiencies, and
iron deficiency anemia and are more commonly observed
in older children. The gastrointestinal presentation of CD
rarely occurs in T1D patients (< 10%), but many patients
with CD and T1D are either asymptomatic (silent CD) or
present only mild symptoms [17,20,22]. Furthermore, the
wide spectrum of CD include also subjects with positive
celiac-related antibodies without diagnostic small-bowel
mucosal villous atrophy. This condition is defined as
potential celiac disease (pot-CD) [23-25]. Data from the
majority of childhood diabetes care centers in Italy showed
that prevalence of pot-CD patients in this population
(higher in females than males) is 12.2%, while the preva-
lence of pot-CD in the CD control population is 8.4% and
only few of them present CD-related symptoms [26].
CD-screening
Diagnosis of CD is regularly due to screening protocols
which are widely recommended and performed. Actually
diagnosis is commonly performed by means of TTG IgA
(confirmed by EMA) or TTG-IgG if IgA-deficiency is
present. Screening has to performed at followed times:
1 )a tt h et i m eo fd i a b e t e so n s et, 2) yearly in the first 4
years of follow up, 3) each 2 years in the successive 6
years of follow up [27,28]. In the presence of CD-related
antibodies positivity it is mandatory to perform bowel
biopsy to confirm diagnosis of CD, even if in very recent
guide-lines of ESPGHAN Society [29] it is proposed that
in evident CD-cases it is possible to avoid biopsy (4
main criteria).
Table 1 Prevalence of CD in patients with T1D in recent literature (2004-2011)
Reference Country N. Age (yr) Screening Prevalence (%)
Cerutti et al. 2004 Italy 4322 11.8 ± 4.2 AGA + EMA 6.8
Contreas et al. 2004 North Italy 357 Children EMA 7
Sanchez et al. 2005 Germany 281 Children AGA + EMA 6.4
Araujo et al. 2006 Brasil 354 Children TG 10.5
Goh et al. 2007 UK 113 Children EMA + TG + AGA 4.4
Larsson et al. 2008 Sweden 300 < 20 EMA 10
Karavanaki et al. 2009 Greece 144 12.3 ± 4.6 TG 4.8
Djuric et al. 2010 Serbia 121 Mean 10.8 TG 5.79
Bhadada et al. 2011 India 189 10.81 ± 7.3 TG 11.1
Gabriel S et al. 2011 Romania 119 11 ± 4 TG 9.2
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GFD should be proposed actually only in patients with
mucosal atrophy.
In patients with overt CD, identifying and treating CD
with gluten free diet (GFD) surely confer benefit in
reducing/resolving malabsorption, infertility, osteoporo-
sis, poor nutrition, impaired growth and long-term
malignancy risks and mortality rates [30-32]. Similarly,
children with T1D and symptomatic CD benefit from
GFD [33] and also metabolic control of diabetes could
be ameliorated [34].
On the contrary, in symptom-free patients weight gain
and bone mineral density (BMD) changes have been non-
univocally described as benefit [35-37]. The different view-
points highlight the need of a prolonged follow up in
patients affected by T1D and asymptomatic CD to clarify
the role of GFD. Some authors argument that GFD in
asymptomatic CD-T1D patients should be opportunely
proposed but not excessively stressed [38,39].
Finally, no definite consensus exists among experts
about to treat by GFD pot-CD patients, in whom recently
it has been suggested that GFD could be a benefit [40].
Concerning to the natural history of patients whit pot-CD,
a recent study shows that 30% of these patients develops
overt CD in a three years follow-up and underlines the
necessity of re-testing [41]. However no data are available
about the follow-up of patients with T1D and pot-CD.
Surprisingly, intestinal inflammation has been described
also in T1D patients without CD-related antibodies and
structurally normal intestinal mucosa [42]. According to
this, our group has observed a gluten-related inflammation
either in rectal either in small bowel mucosa of children
with T1D [43,44]. It can be speculated that gluten could
be an optimal candidate to stimulate an abnormal innate
immune reaction in intestinal mucosa due to its pro-
inflammatory characteristics. It remains a crucial issue to
establish if the extended intestinal inflammation in T1D is
gluten-dependent and whether it precedes the occurrence
of the disease.
Bone impairment: a hidden threat
In patients with only T1D it is possible to demonstrate
impairment of bone metabolism and structure, specially in
relationship with duration and/or poor control of diabetes
[45]. Furthermore CD also have been underlined as cause
of bone impairment. Clinical observation indicates that
clustering of three autoimmune diseases (T1D, CD and
generally thyroiditis) significantly increases the occurrence
of osteopenia (37.5%). It is possible that bone impairment
might be considered not only a complication due to endo-
crine or nutritional mechanisms, but also a consequence
of an immunoregulatory imbalance [46]. In fact osteoclasts
are now considered as the innate immune cells in the
bone, since they are able to produce and respond to
cytokines and chemokines. Bone remodelling involves
complex interactions between osteoclasts and other cells
in bone microenvironment (marrow stromal cells, osteo-
blasts, macrophages, T-lymphocytes and marrow cells)
[47]. Several cytokines, like the cytokine receptor activator
of NFkB ligand (RANKL) and the macrophage colony
stimulating factor (M-CSF), can promote osteoclast forma-
tion and activity. Also osteoprotegerin (OPG), a circulating
secretory glycoprotein, could have a role in bone remodel-
ling in children with T1D because it could promote differ-
entiation, fusion, survival, activation and apoptosis of the
osteoblasts. Alterations or abnormalities of the RANKL/
OPG system have been implicated in different metabolic
bone diseases characterized by increased osteoclast differ-
entiation and activation, and by enhanced bone resorption
[48].
In patients affected by both T1D and CD, the risk of
developing osteopenia is also influenced by the compli-
ance to GFD. In fact, osteopenia occurs more frequently
in patients with diabetes and CD with poor compliance
to GFD [49]. Recent observations indeed indicated an
imbalance of cytokines relevant to bone metabolism in
untreated celiac patients’ sera and the direct effect of
these sera on in vitro bone cell activity. In particular the
RANKL/osteoprotegerin (OPG) ratio was increased in
patients not on gluten-free diet [46].
In conclusion osteopenia seems to be a new occult
problem in CD patients, in T1D patients and in patients
with two or three immunological diseases, depending
also on GFD.
GFD composition
Diet is a fundamental part of the treatment in both T1D
and CD. However GFD composition could present some
problems for diabetic people (Table 2).
The glycemic index (GI) provides an indirect measure of
the ability of a food to raise blood glucose.GI is retained a
direct index of absorption of carbohydrates, being: “the
area under curve of blood glucose after eating a food con-
taining a determined quantity of carbohydrate”.W h i t e
bread (GI = 100) is usually compared as reference value.
In normal subjects ingestion of foods with high GI leads
to a rapid blood glucose increase causing a marked insulin
response. In diabetes, diet containing food with high GI is
Table 2 Variations of HbA1c, BMI gain and height
velocity after GFD in children with T1D-CD
Reference HbA1c BMI gain Heigh velocity
Westman et al. unchanged Unchanged unchanged
Saukkonen et al. unchanged Increased unchanged
Amin et al. reduced Increased unchanged
Saadah et al. unchanged Increased unchanged
Valletta et al. unchanged Unchanged unchanged
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deficiency (T1D) or insulin inefficacy (type 2 diabetes) the
normal insulin response is not obtainable; traditionally the
common diet of the diabetes people consists principally in
foods with low GI. In 2002 American Society for Clinical
Nutrition published an international table, revised by an
older published of the sixties, which shows the GI of most
common foods, evaluated in comparison to glucose and to
white bread [50], (Table 3) where gluten-free products
have higher GI-foods than similar products gluten con-
taining. In Paker’s study [51] six types of gluten-free foods
are compared with white bread containing gluten. These
foods were eaten from 11 adult patients with type 2 dia-
betes and blood glucose was measured after eating. Results
showed no difference about GI among gluten-free foods
and those containing gluten. On the contrary, Berti et al.
show a higher blood glucose curve for gluten-free foods,
although with similar insulin curves and with contradictory
results between in vivo and in vitro analysis. (Table 4),
[52]). Specific studies both in healthy patients and in type 1
and type 2 diabetic patients should be necessary, particu-
larly in pediatric age.
In addition, gluten-free foods are prepared using corn
flour, rice and wheat, where the percentage of fiber, carbo-
hydrate, fats and micronutrients isn’t completely known.
Scarce contrasting data generally describe in gluten free
foods composition few proteins, more fat and few fibers
than gluten containing foods. (from SCHAR website and
Ministry of Agriculture website, Tables 5 and 6). In addi-
tion in the review of Kupper [53] GFD seems to can be
the cause of a multiple nutrients deficiency, especially of
vitamin B, vitamin D, calcium, magnesium, iron, zinc, but
sources of his information are not well documented.
Finally Berti et al. [52] reported higher amount of fats in
gluten-free bread then those with gluten, but the same
amount of fibers (Table 7).
Compliance/adherence to GFD and quality of
life (QOL)
Adherence to GFD among T1D-CD patients, in our
experience, is generally good in patients who experi-
enced clear clinical symptoms of CD, but is scarce
among patients with few symptoms or asymptomatic. In
Table 8 a summary of the data of literature is presented,
but authors did not specify whether patients had experi-
enced symptoms; data of our group are also presented
[36]. In contrast with T1D population, dietary compli-
ance in CD patients (without T1D), seems to be higher:
approximately 73% of patients followed the diet strictly
[54]. Probably for a patient with T1D, already engaged
in coping day by day a complex chronic disease, the
addition of a second “limiting” condition, is a remark-
able discomfort [55]. Consequently, in the case of dou-
ble diagnosis (T1D + CD), it is very difficult to manage
patients who did not experienced CD symptoms.
Studies on the compliance/adherence to GFD in non
diabetic people showed that, in relation to the social life,
children usually have a better compliance to GFD than
adults [56]. In a follow-up of 10 years in the Netherlands
conducted on children from 2 to 4 years who received CD
diagnosis by screening, authors described a general
improvement of health without deterioration in QOL [57].
In concordance Kolsteren showed that the QOL of celiac
children is quite similar to that of other children [58].
Usually the difficulty with the diet occurs when the patient
became adolescent, because she/he needs to feel equal to
peers, especially when she/he decides to go out to eat and
more acutely she/he feels limits imposed by GFD. Accord-
ing to Wagner et al. [59] celiac adolescents non compliant
with GFD reported a lower general QOL, more physical
problems, a higher burden of illness, more family troubles,
and more problems in leisure time than adolescents who
are compliant with GFD. No differences between compli-
ant patients with CD and adolescents without any chronic
condition were found in all QOL aspects.
It is also important remark that the balance between
GFD adherence and daily life is difficult to achieve for the
child/adolescent who is also affected by an other chronic
disease such as T1D. The need to coordinate insulin ther-
apy with proper nutrition and a healthy lifestyle, in order
to maintain adequate metabolic control, is already a con-
siderable effort for the young T1D-patient and families
[60]. Rebellions are frequent especially in adolescents, who
are already feeling diabetes as very “invasive” for all the
aspects of daily life and who receive a further “restriction”
constituted by the GFD. Consequently there it could be
the risk, especially if this proposal is not properly, to elicit
a response of complete rebellion which will endanger not
only the adherence to the GFD [36,54,55], but also the
entire management of T1D, causing a sharp deterioration
of general compliance and increasing the risk of severe
acute complications (recurrent ketoacidosis, unawareness
Table 3 GI of some gluten-free foods, compared to
glucose and white bread
GI glucose = 100 GI bread = 100
Gluten-free multigrain bread 79 ± 13 113
Gluten-free white bread 76 ± 5 108 ± 7
Gluten-free fiber enriched bread 73 ± 4 104 ± 5
Table 4 GI of gluten-free foods evaluated in vivo,
compared to white bread (= 100)
Food GI
Gluten-free bread 230
Gluten-free pasta 255
Quinoa 186
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further limit could be a trigger also of eating disorders in
adolescent patients, being eating disorders not rare and
previously reported in diabetes. Regarding QOL, Sud et al.
[61] in children with T1D-CD showed that the double
diagnosis appears to have a minimal impact on QOL, even
if patients’ parents reported a very important difficulty on
management. It is interesting that not significant differ-
ences in QOL were observed with regard to age at CD
diagnosis and duration, or on the basis of adherence with
a GFD. Furthermore parents of T1D-CD children did
express greater concern about their child’ss o c i a l
functioning.
Conclusions
Prevalence of CD among children with T1D is signifi-
cantly higher than in non diabetic children. In a large
proportion CD is asymptomatic or characterized by
modest/atypical symptoms. Periodic screening of CD
auto-antibodies is mandatory. CD diagnosis requires the
biopsy confirmation and it is necessary to prescribe
GFD in the presence of mucosa impairment. Concerning
the clinical benefits of GFD in T1D-CD patients, data
are contrasting, except in severely symptomatic patients.
Osteopenia seems to be a new occult problem in CD
patients, in T1D patients and in patients with two or
three immunological diseases, depending also on GFD.
Table 5 Nutritional composition of gluten free and containing gluten foods
Products PROT (g) CHO (g) SUGARS (g) FATS (g) FIBER (g) KCALS
Flour 00 11 77.3 1.7 0.7 2.2 340
Gluten-free flour 1.2 86.3 1.5 0.8 4.5 357
Crackers containing gluten 9.4 80.1 2.5 10 2.8 428
Gluten-free crackers 5.2 74.7 5.2 12.7 2.9 434
Cereal flakes containing gluten 6.6 87.4 10.4 0.8 3.8 361
Gluten-free cereal flakes 8 80 5.3 16 5 361
Rusks containing gluten 11.3 82.3 2.2 8.2 3.5 408
Gluten-free rusks 4.8 82.9 5.4 1.4 3.6 425
Pasta containing gluten 10.9 79.1 4.2 2.5 2.7 353
Gluten-free pasta 9 73.7 0.4 7.9 2.2 353
Biscuits 6.6 84.8 18.5 14.3 2.6 416
Gluten-free biscuits 2.7 79.9 16.1 0.8 459
Table 6 Portion size, macronutrient and micronutrient composition of test meal.
White
bread
GF
biscuits
GF white Unsliced
bread
GF fibre Sliced
bread
GF white Sliced
bread
GF fibre Unsliced
bread
GF
pasta
Serving (g) 107 73 101 119 101 119 64
Energy (kcals) 232 335 221 225 221 236 230
Protein (g) 8.1 2.55 3.03 3.57 3.03 3.57 5.05
Carbohydrate
(g)
50 50 50 50 50 50 50
(g sugars) 3.21 17.5 4.54 5.36 4.50 5.35 0.61
Fat (g) 1.39 13.87 1.01 1.19 1.01 2.38 1.02
(g satured) 0.32 4.38 0.50 0.60 0.50 1.19 0.32
Fibre (g) 1.61 2.92 1.01 5.95 1.01 7.7 0.96
Sodium (g) 0.56 0.37 0.51 0.47 0.51 0.35 0.05
GF = gluten-free
Table 7 Weight of meal and nutrient composition of 50 g available carbohydrate portions of the foods studied as
served.
Tests foods Weight of meal (g) Protein (g) Water (g) Carbohydrate (g) Fat (g) Total dietary fibers (g)
Bread 100 9.4 31.4 50 3.6 2.8
GF Bread 125 5.7 38.5 50 9.7 3.9
Gf Pasta 156 3.2 61.2 50 0.6 2.1
Quinoa 320 3.4 75.9 50 2.0 2.8
GF = gluten-free
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any disadvantages regarding of glycemic index, fibers,
percentage of fat and micro-nutrients. Data are not uni-
vocal on this point.
Communication of the need of GFD in patients with
T1D-CD is particularly delicate, especially in adolescents
where it is possible to trigger rebellion behaviors. The
coexistence of these two diseases in the same patient
requires care by clinicians and probably a specific psy-
chological approach.
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